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Obesity has become one of the major threats for public health in industrialised world among adults, but 
also among adolescents and children. It is inﬂ uenced by the interaction of genes, nutrition, environment, 
and lifestyle. Environmental and lifestyle risk factors include foetal and lifelong environment, nutrient 
quality, chemical and microbial exposure, and psychical stress, all of which are important contributing 
inﬂ uences. Removing or limiting chemical and pharmaceutical obesogens from human environment could 
make a difference in the growing epidemic of obesity.
Additionally, nutrigenomics describes how modiﬁ cations in individual diets can improve health and 
prevent chronic diseases, as well as obesity, by understanding the effects of a genetic proﬁ le in the interaction 
between food and increase in body weight. Furthermore, individual genetic variations in genome represent 
an individual′s predisposition for obesity. Therefore, the use of individual genetic information, avoiding 
obesogens, and a healthy lifestyle could help to improve the management of obesity and maintain a healthy 
weight.
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The growing prevalence of obesity and the fact 
that its management is mostly ineffective are opening 
novel fields of research - investigation of genes, 
environment, and their interactions with the intention 
to create a concept of personalised medicine and 
nutrition (1).
Obesity and its implications for human health 
decrease the quality of life and life expectancy 
considerably, as they increase the risk of a great 
number of chronic diseases (2-10; table 1). Excess 
weight and obesity are the consequences of a higher 
energy intake and lower energy expenditure, which 
results in a positive energy balance (11). Several 
biological changes in our body are related with the 
state of overweight and obesity (Figure 1).
Obesity is a disease which affects not only the 
individual, but also the public health. It is inﬂ uenced 
by many factors such as genetic and epigenetic 
predisposition, metabolic, hormonal, environmental, 
behavioural, social, and cultural aspects (12). This is 
why it is important to better understand obesity and 
its aetiology and ﬁ nd more effective prevention and 
treatment tools.
Genetic aspect of obesity
Individual human differences and genetic variations 
inﬂ uence the risk of becoming obese (11). At present, 
over 100 genes are under discussion for their effect 
on obese phenotypes. The latest update of the Human 
Obesity Gene Map, which was created in 2005, 
focuses on 253 groups of genes related to obesity (13). 
This catalogue of obesity genes shows that putative 
loci affecting obesity-related phenotypes are situated 
on all chromosomes except Y. Table 2 displays ﬁ ve 
categories of the most investigated obesity-related 
genes in recent years (13-16, Figure 1).
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The studies on both humans and animals showed 
that different genes play roles in different responses 
to weight gain or weight loss, and that body defence 
against losing fat/weight is greater than that against 
gaining fat/weight (17). Also, the weight loss response 
to (dietary) interventions varies. Many genes involved 
in the regulation of energy balance, appetite, lipid 
metabolism, and adipogenesis have been reported to 
affect the risk of dietary intervention failure in some 
individuals. Some of these genes have already been 
mentioned: β-adrenergic receptor (ADBR), 
uncoupling proteins (UCPs), leptin (LEP), leptin 
receptor (LEPR), melanocortin receptor 3 (MC3R), 
pro-opiomelanocortin (POMC), and interleukin 6 
(IL-6) (18, Table 2).
In studies involving adult monozygotic twins (19, 
20) who were overfed and whose energy intake or 
exercise were restricted (21-23), it was shown that the 
predisposition to increase or decrease body fat was 
genetically based (1). 
Mammes et al. (2001) reported that a G>A 
transition at position -2549 in the promoter region of 
the LEP gene is associated with obesity and that 
carriers of the -2549A allele have higher leptin levels 
and lower weight loss as a response to low calorie 
intake (24, 25). Furthermore, carriers of a variant C 
allele in the LEPR gene [Ser (T) 343Ser (C)] have lost 
more weight in response to a low calorie intake than 
the noncarriers (26).
In a study of the Lys656Asn variant within LEPR, 
homozygotes for the Lys656 allele had a considerable 
loss of body weight, fat mass, waist circumference, 
and a decrease in body mass index (BMI), systolic 
blood pressure, and leptin levels, compared to the 
carriers of the Asn656 allele (27). Some studies have 
investigated the effect of a polymorphism in the 
peroxisome proliferator-activated receptor γ (PPARγ) 
gene, Pro12Ala. Lindi et al. (28) showed that Ala12 
carriers increased body weight considerably in a 
period of 10 years. However, Ala12Ala homozygotes 
had, in the same period of time, lower levels of fasting 
plasma insulin, regardless of the increased body 
weight. In another study, Ala12 carriers on a 
hypocaloric diet lost almost the same body weight as 
Pro12 homozygotes during a period of six months, 
but unlike Pro12 homozygotes, they gained more 
weight after the hypocaloric treatment was completed 
(29).
Candidate gene variants for polygenic obesity 
appear to disrupt pathways involved in the regulation 
of energy intake and expenditure and include 
adrenergic receptors, uncoupling proteins, PPARγ, 
POMC, melanocortin receptor 4 (MC4R), and a set 
of single nucleotide polymorphisms in the fat mass 
and obesity (FTO) locus. Obviously, obesity polygenic 
character involves complex gene-gene and gene-
environment interactions and their mutual interactions 
that result in multi-factorial obese phenotypes (for 
reviews see 30-32).
Environmental obesogens
Human diseases are entirely or partially caused by 
environmental chemicals, which introduce genetic 
and/or epigenetic changes in the genome. Heritable 
changes in gene expression exclude any modiﬁ cation 
of the primary DNA sequence. However, they lead to 
chromatin remodelling through DNA methylation, a 
complex set of histone modiﬁ cations, and the inﬂ uence 
of non-coding RNAs. Besides the changes in the 
epigenetic status (33), lifestyle, dietary intakes, and 
environmental chemicals affect cell transcriptional 
factors (34), hormones (35, 36), inflammatory 
mechanisms (37), and gut microbiome in certain 
organisms (38-41), all of which are contributing 
factors for obesity epidemic (42-44, Figure 1). The 
Figure 1 The physiological changes associated with obesity
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most important molecular and/or cellular changes that 
are reﬂ ected on obesity phenotypes appearance are 
further described.
Obesogens (Figure 1) are foreign endocrine 
disrupting chemicals (EDCs) that inappropriately alter 
normal development and/or homeostasis of lipid 
metabolism, adipogenesis, fat storage, obesity, and 
type 2 diabetes (4, 45-48). EDCs can interfere with 
normal functions of the endocrine system by disrupting 
the balanced system of hormones that regulate vital 
body functions such as growth, stress response, sex 
development, behaviour, ability to reproduce, 
production and utilisation of insulin, and metabolic 
rate. Recent experiments on animals conﬁ rmed that 
EDCs can disrupt the gene-controlled, normal 
signalling systems that determine every aspect of 
foetal development. Furthermore, epidemiology 
studies indicate that exposure to EDCs during the 
development of a foetus is associated with excess 
weight and obesity later in life (49).
It has been proposed that dangerous environmental 
obesogens can be categorised into the following 
groups of compounds: endocrine disrupting chemicals 
organotins and bisphenol A (BPA), perﬂ uorooctanoic 
acid, diisobutyl phthalate, and pharmaceutical 
obesogens such as thiazolidinediones: rosiglitazone 
and pioglitazone (45, 47, 48).
Organotins are widespread persistent environmental 
organic pollutants with potent endocrine-disrupting 
properties in both vertebrates and invertebrates. 
They are used as fungicides and pesticides in crops, 
antifungal agents in wood treatments, slimicides in 
Table 1 Obesity related diseases or disorders
Disease / disorder Relation with obesity Source/publication
Type II diabetes 80 % correlation of type II diabetes and obesity
85 % of children with type II diabetes are obese
Term “diabesity” underscores the strong 
connection
Lau, 2008 (2)
Cardiovascular diseases Correlation with obesity in 70 % of cases Lau, 2008 (2)
Metabolic syndrome 
Hypertension









Gout, liver disease, asthma and
pulmonary problems, gall bladder
disease, kidney disease, osteoarthritis





Connection with colon and breast cancer 42 %
Obesity associated with breast cancer recurrence 
and mortality through low physical activities, high 
calorie and fat intake, and changes in hormones 
(high oestrogen production in adipose tissue)
More aggressive forms are diagnosed in men with 
higher BMI (by 15 % to 21 % higher risk of fatal 
prostate cancer or biochemical recurrence)
12 % to 20 % of prostate cancer deaths connected 
with obesity
Lau, 2008 (2)
Chlebowski, 2005 (5), 
Sauter et al., 2008 (6), 
Rose and Vona-Davis, 
2010 (7)
Strom et al.,2005 (8),
Cao and Ma, 2011 (9)
Chronic musculoskeletal problems, 
lumbago, skin problems, obstructive 
sleep apnoea
Decreased physical activity, BMI >30 Kanasaki and Koya, 
2011 (10)
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industrial water systems, marine antifouling agents, 
in polyvinylchloride plastics, and in the textile industry 
(45, 47, 48). Contaminated drinking water, agricultural 
products, seafood, and leaching from plastics are the 
most frequent sources of organotins (50-52). 
Organotins such as tributyltin (TBT) and triphenyltin 
are potent activators of nuclear hormone receptors 
retinoid X receptor (RXRα, -β, and -γ) and peroxisome 
proliferator-activated receptor γ which regulate 
adipocyte number, size, and function (53). Moreover, 
the organotin compound tributyltin, an agonist of both 
retinoid X receptor and peroxisome proliferator-
activated receptor γ, alters the fate of stem cell 
compartment by sensitising multipotent stromal stem 
cells to differentiate into adipocytes (49). More 
recently, studies have confirmed that TBT and 
tetrabromobisphenol A modify hypothalamic gene 
regulations resulting in hypothalamic dysregulations 
(54).
Bisphenol A as a component of polycarbonate 
plastics is widely used in numerous products such as 
polycarbonate baby bottles, beverage containers, the 
linings of food cans, dental composites, and sealants 
(4). BPA has a potential to bind to the nuclear 
oestrogen receptor and interact with a variety of other 
targets in mammalian cells. In addition to acting as an 
androgen receptor antagonist, BPA interacts with 
thyroid hormone receptors (55). A variety of 
abnormalities in the female and male reproductive and 
mammary gland tissues were found after perinatal 
exposure to low doses of BPA (55). Exposure to low 
doses of BPA during prenatal and neonatal periods 
affected both mice and rats insomuch as their body 
weight increased (57-60).
Perfluorooctanoic acid and phthalates can 
negatively affect the adipose homeostasis and lipids. 
These classes of chemicals include various 
perﬂ uoroalkyl compounds and phthalate plasticisers 
that are widely used as surface repellents and 
surfactants.
Pharmaceutical obesogens, rosiglitazone and 
pioglitazone (thiazolidinediones) are PPARγ agonists, 
which improve serum triglycerides and glycaemic 
control for type 2 diabetes. However, side effects 
mediated by PPARγ include weight gain in diabetics 
when such agonists are used for a prolonged time (61, 
62), an increase in cardiovascular risks and, for 
rosiglitazone, an increased risk of acute myocardial 
infarction, stroke, and heart failure (63).
EDCs can probably affect multiple target 
mammalian cells through a variety of mechanisms. 
The most likely mechanism involves direct binding 
to nuclear receptors such as oestrogen receptor α 
and/or PPARγ acting as agonists. Another possibility 
would be their binding to nuclear receptors and acting 
as antagonists. The indirect EDCs′ effect involves 
disrupting hormone levels through the inhibition of 
enzymatic activity or the activation of expression of 
P450 enzymes (4).
All proposed mechanisms may also interact with 
each other creating a complex network. However, in 
the future, when research studies will have clariﬁ ed 
the network of reactions in the cell, a complete picture 
of interactions will be available.
Figure 2  Possible targets of obesogens. Environmental obesogens inﬂ uence a variety of molecular and/or cellular targets that 
may act either alone or with each other creating a complex network that affects gene expression and results in obesity 
phenotypes (abbreviations: miRNA - microRNA, PPARs - peroxisome proliferator-activated receptors, RXRs- retinoid 
X receptors, ER - oestrogen receptor, CYP19 - Cytochrome aromatase p450, PH – peptidergic hormones, BMI - body 
mass index).
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Nutrigenomics: nutrient and gene interaction
Nutrigenomics investigates the effect of interactions 
between lifestyle, genes (individual genetic variations 
in single-nucleotide polymorphisms), and food on 
different/unique responses to food among individuals 
and consequently, the relationship of that response 
with the aetiology of common chronic diseases (64, 
65).
Evolution has brought about minor changes of 
human genome but these are able to inﬂ uence an 
individual′s metabolism and response to food (66).
Nutrigenomics is related to the human genome 
and, as already mentioned, it tries to describe the cause 
of some chronic diseases (obesity, diabetes mellitus, 
cancer) through the interactions between genes and 
the environment (food, pesticides, and pharmaceuticals) 
(67). It also attempts to create a personalised nutrition 
for every individual, according to a unique genetic 
proﬁ le (68, 69).
The individual advice regarding nutrition and 
lifestyle changes should be based on an analysis of 
genes, in order to achieve a better health status (70). 
When managing multifactorial diseases (including 
obesity), it is crucial to point out that some genotypes 
(haplotype combinations) are susceptible to nutrition 
treatments and that genetic differences among 
individuals could inﬂ uence the occurrence of obesity 
and its health implications (71).
It is important to emphasize that some nuclear 
transcription factors (e.g. PPARγ) are more sensitive 
to nutrition treatment/interventions than others. For 
example, Kim et al. (72) selected 31 genes in the liver 
of obese C57BL/6J mice and showed that genes 
involved in fatty acid beta-oxidation, fatty acid 
synthesis, and gluconeogenesis were upregulated, but 
genes involved in sterol biosynthesis, insulin 
signalling, and oxidative stress defence system were 
downregulated with a high-fat diet.
Hence, nutrigenomics aims to develop a diet based 
on individual genetic variants (73) through the 
research of the inﬂ uence of such variants on the 
connections between food and aetiology of obesity 
(74). It has been shown that individuals with high 
genetic predisposition for obesity will easily gain 
weight and will have a different response to weight 
treatment compared to those with low genetic 
predisposition (11). Results from studies show that 
high-fat diets may lead to obesity. One study compared 
the body mass indexes of individuals according to how 
much fat they ate and showed that the number of obese 
individuals was higher among those on a high-fat diet 
compared with those on a low-fat diet. Also, their body 
weight changed differently in response to the 
restriction of calories from fat (1, 75).
It is known that interactions between genes, gender, 
and the environment alternate the development of a 
disease. In the Framingham Heart Study, interactions 
between a promoter polymorphism at the apolipoprotein 
A1 gene, gender, and dietary poly-unsaturated fatty 
acid intake modulated plasma concentrations of high-
density lipoprotein cholesterol (76), high levels of 
which protect from cardiovascular diseases.
In another study, Sotos-Prieto et al. (77) showed 
that the rs1466113 polymorphism in the somatostatin 
receptor 2 gene was associated with anthropometric 
variables in the Mediterranean population with 
differences in food intake.
Interactions between genes and the environment 
have also been associated with a decrease in the levels 
of hormone adiponectin. These changes in adiponectin 
Table 2 The list of obesity genes
Genotype in obesity Genes
Thriftiness (low metabolic rate,
 inadequate thermogenesis)
β-2-adrenergic receptor and β-3 (ADRB2; ADRB3), uncoupling protein 1, 2, 
and 3 (UCP1, UCP2, UCP3)
Hyperphagia (abnormal regulation
of hunger and satiety)
dopamine receptor D2 (DRD2); 5-hydroxytryptamine (serotonin) receptor 2C 
(HTR2C); leptin (LEP); leptin receptor (LEPR); melanocortin receptor 4 
(MC4R); nuclear receptor subfamily 3, group C, member 1 (NR3C1)
Low rate of lipid oxidation
angiotensin-converting enzyme (ACE), adiponectin (ADIPOQ), guanine 
nucleotide binding protein, β -3 subunit (GNB3), hormone sensitive lipase 
(LIPE), low density lipoprotein receptor (LDLR)]
Adipogenesis (fat storage)
peroxisome proliferator-activated receptor γ (PPARγ); vitamin D receptor 
(VDR), resistin (RETN), interleukin-6 (IL6); tumour necrosis factor α (TNF)]
Low physical activity dopamine receptor D2 (DRD2); melanocortin receptor 4 (MC4R)
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level can cause obesity. Ntalla et al. (78) investigated 
whether variants of adiponectin gene interacted with 
food/speciﬁ c components of food and inﬂ uenced the 
levels of adiponectin. The results of the study, 
conducted on healthy school-aged children, showed 
that a single nucleotide polymorphism rs1501299 and 
ﬁ bre interaction was signiﬁ cantly associated with 
adiponectin levels.
Consumption of reﬁ ned carbohydrates contributes 
to the development of obesity and type 2 diabetes 
mellitus. Most genes of the metabolic pathways of 
carbohydrates are associated with quantitative trait 
loci for obesity and many for type 2 diabetes mellitus. 
It is signiﬁ cant to underline that metabolic pathway 
genes have a role in the development of a disease and 
different appearance of such disease among individuals, 
which results in different risks for a speciﬁ c disease 
(79).
Inflammation plays an important role in the 
development of health implications of obesity (80) 
and fat tissue is essential, as obesity is associated with 
inﬂ ammation (81): adipocytes, or fat cells, secrete 
pro- and anti-inflammatory adipokines (82-84). 
Reduced adiponectin (85, 86) and increased C-
reactive protein (87, 88) concentrations are associated 
with cardiovascular disease and type 2 diabetes. A 
decrease in inflammation can prevent health 
complications associated with obesity. Some food has 
anti-inﬂ ammatory effects (89) and has been associated 
with the decrease in the prevalence of some chronic 
diseases related to dietary and lifestyle habits (90, 91). 
In line with this, Bakker et al. (92) conducted a dietary 
intervention with antioxidative substances such as 
resveratrol, green tea extract, α-tocopherol, vitamin 
C, omega-3 polyunsaturated fatty acids, and tomato 
extract, and showed that these compounds inﬂ uenced 
inflammatory processes, oxidative stress, and 
metabolism in individuals.
How to maintain a healthy weight after low calorie/
low energy treatment is the issue of many studies (93). 
Peripheral blood mononuclear cells (PBMCs) can help 
to investigate the response to nutrition interventions 
(94), and Goyenechea et al. (93) demonstrated the role 
of pro-inﬂ ammatory status in weight changes in obese 
subjects receiving a low-calorie diet (LCD) during a 
six-month weight maintenance period. This could help 
to create individual dietary treatments for maintaining 
healthy weight. In another study, Goyenechea et al. 
(95) analysed the expression of two interacting genes 
(RIPK3 and RNF216) in obese subjects receiving LCD 
and the authors concluded that the expression of these 
two genes in PBMCs could identify those obese 
subjects who will regain more weight after a successful 
initial weight loss.
Personalised nutrition
Nutrigenetics and personalised nutrition can give 
every individual an advice on a diet that is in line with 
personal genetic proﬁ le (96). Arkadianos et al. (70) 
showed that nutrigenetically (gene-nutrition) tailored 
diets result in better compliance of patients, longer 
reduction of body weight, and improvement in glucose 
blood levels.
Negative public opinion on genetic testing in order 
to create a unique personalised diet, may inﬂ uence the 
success of nutrigenomic intervention. Steward-Knox 
et al. (97) conducted a study in order to determine the 
opinion of people in Europe on genetic testing and 
individually tailored nutrition. Individuals who were 
willing to undertake a genetic test for creating 
personalised dietary interventions in most cases had 
high blood cholesterol levels, central obesity, and/or 
high levels of stress, whereas individuals who were 
not obese were not willing to have a nutrigenomic 
intervention.
To summarise, obesity involves an interaction 
between genetic and environmental factors (98). This 
is the reason why it is important to include gene–
environment information in the management and 
prevention of excess weight. However, some issues 
of weight management are still crucial (15): 
identiﬁ cation of markers that can predict the results 
of dietary interventions; development of methods for 
identifying biomarkers; simple and available 
measurement of markers; and responsible use of 
individual genetic information.
CONCLUSION
Obesity is caused by the combined impact of 
genetic, environmental, and lifestyle factors. It 
represents a risk factor for cardiovascular and 
metabolic diseases (hypertension, type 2 diabetes, 
insulin resistance, hyper-insulinaemia, gout, liver 
disease, gall bladder disease), kidney disease, 
reproductive problems, sleep apnoea, osteoarthritis, 
and multiple types of cancer. Overall, it is the culprit 
for many current health problems in the population of 
western countries. As the prevalence of obesity 
continues to increase, it is important to better 
understand the genetic aspect of obesity and the 
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importance of the interactions between genes, genome, 
epigenome, and the environment obesogens. The 
disputable and known pharmaceutical  and 
environmental obesogens, such as thiazolidinediones, 
organotins, perfluorooctanoic acid, diisobutyl 
phthalate, and bisphenol A, are still used today and 
should be banned and removed from the 
environment.
Also, although nutritional interventions can reduce 
body mass, the process of gaining weight can be 
affected by an individual genetic proﬁ le. Nutrigenomic 
approach allows us to explore these interactions and 
apply them in the management of obesity. Many genes 
in which polymorphisms can affect the development 
of obesity are identiﬁ ed, but further investigations are 
still necessary; especially in the development of new 
diagnostic methods, categorisation of obesity based 
on speciﬁ c genotype, creation of personalised nutrition 
for treating excess weight, and the most important, 
effective prevention tools. To conclude, the future of 
nutrigenomics science brings many challenges for 
scientists, practitioners, caregivers, and individuals. 
Investigating obesity and its significant health 
implications is and will continue to be important, as 
more effective ways need to be found to resolve this 
public health problem.
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Sažetak
PRETILOST – MEĐUDJELOVANJE GENOMA I OKOLINE
U industrijaliziranom svijetu među odraslim osobama, adolescentima i djecom pretilost je postala 
jedna od glavnih prijetnja za javno zdravlje ljudi. Njezina je pojavnost pod utjecajem međudjelovanja 
gena, prehrane, okoliša i načina života. Važni čimbenici rizika vezani su uz okolinu i način života, 
uključujući čimbenike prisutne već u okruženju fetusa te one prisutne tijekom cijeloga života kao što su 
kvaliteta prehrane, izloženost kemikalijama, mikroorganizmima i psihičkom stresu. Uklanjanje ili 
ograničavanje kemijskih tvari i lijekova koji uzrokuju pretilost iz ljudske okoline moglo bi utjecati na 
opadanje epidemije pretilosti.
Dodatno, nutrigenomika opisuje kako se promjenama u prehrani pojedinca može poboljšati zdravstveno 
stanje i spriječiti razvoj kroničnih bolesti, uključujući i pretilost, a pritom je potrebno poznavati utjecaj 
genskog proﬁ la na međudjelovanje hrane i porasta tjelesne mase. Nadalje, genske varijacije u genomu 
pojedinih osoba stvaraju i njihovu predispoziciju za razvoj pretilosti. Stoga se zahvaljujući informacijama 
o genskom proﬁ lu pojedinca, izbjegavanjem tvari koje uzrokuju pretilost i zdravim načinom života može 
poboljšati kontrola pretilosti i održavati optimalna tjelesna masa.
KLJUČNE RIJEČI: geni, nutrigenomika, prehrana, tvari koje uzrokuju pretilost
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